Innovation and a new contract

After having discovered the TRO19622 molecule (olesoxime) and obtained funding in 2009 of € 6.7 M over three years from the Association Française contre les Myopathies (AFM) to develop this drug to fight spinal muscular atrophy, the Marseilles-based pharmaceutical company Trophos has announced the discovery of a second molecule in the cholesterol oxime family, TRO40303.
 
Specialized in clinical research in the fields of neurology and cardiology, Trophos has in fact brought to light a new molecule that could be used to protect the heart tissue when treating myocardial infarction, more commonly known as a heart attack. Pre-clinical studies have shown that it significantly reduced ischemia-reperfusion injury that occurs after a heart attack when the blood supply is restored to the heart tissue. Soon to enter phase1 trials, the TRO40303 molecule is due to be tested on volunteers during the second half of 2010.
 
On July 19, Trophos signed an agreement with Actelion for an exclusive option on its buy-out. The agreement is part of a strategy to optimize clinical studies and speed up the availability of its drugs to patients.

This first commitment by Actelion, a leading Swiss pharmaceutical company employing 2500 staff worldwide, could guarantee Trophos sustainability in its future development.